Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck faces significant challenges, including increased competition and regulatory scrutiny for Keytruda. Keytruda is facing potential threats from competitors like Summit Therapeutics ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

Pfizer is offering research grants to support projects advancing knowledge of the importance of PCSK9 in cardiovascular disease, the target of its late-stage drug candidate bococizumab.

Chasing Merck, AstraZeneca's PCSK9 inhibitor lowers cholesterol in phase 1 test Shanghai-based YolTech will continue its work preclinically developing YOLT-101, with Shenzhen, China-based Salubris ...

Merck has other promising candidates in its late-stage pipeline like MK-0616, an oral PCSK9 inhibitor for hypercholesterolemia, tulisokibart, a TL1A inhibitor for ulcerative colitis and Daiichi ...

Sanofi and Regeneron have announced positive results from trials of novel drug alirocumab, which targets PCSK9, in people with hypercholesterolemia. The results of the four phase III ODYSSEY ...